Thus, the measurements that include both LDL-C and VLDL-C (such as apoB and non-HDL-C) should be more reflective of overall ASCVD risk and new therapies should implement the pharmacological control of these lipoproteins. The gene discussed is APOB; the disease is atherosclerosis.